Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
暂无分享,去创建一个
S. Loibl | L. Gianni | C. Lathia | S. Siena | G. Bianchi | C. Zamagni | C. Peña | S. Salvagni | Guenter Raab | N. Laferriere | L. Bergamini
[1] C. Robert,et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. , 2009, Journal of American Academy of Dermatology.
[2] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[3] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[4] V. D’Hondt,et al. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. , 2008, The oncologist.
[5] N. Harbeck,et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. , 2008 .
[6] X. Pivot,et al. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. , 2008, European journal of cancer.
[7] G. Linette,et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Rugo,et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Takimoto,et al. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials , 2008, Cancer Chemotherapy and Pharmacology.
[11] John Smeraglia,et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.
[12] J. Elting,et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis , 2007 .
[13] W. Carney. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers , 2007, Expert review of molecular diagnostics.
[14] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[15] W. Carney,et al. Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer , 2006, Cancer.
[16] S. Rafii,et al. The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma , 2006, International journal of cancer.
[17] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Rosner,et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Hilsenbeck,et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. , 2006, Cancer research.
[20] R. Neumann,et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. , 2006, Anticancer research.
[21] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. Carney,et al. Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy , 2005, Cancer.
[24] J. Wood,et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] C. Hudis,et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[27] R. Neumann,et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. , 2004, Oncology reports.
[28] Terry L. Smith,et al. Is breast cancer survival improving? , 2004, Cancer.
[29] W. Gullick,et al. The type I growth factor receptors in human breast cancer , 2004, Breast Cancer Research and Treatment.
[30] G. Sledge,et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.
[31] S. Eppenberger-Castori,et al. Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients , 2000, International journal of cancer.
[32] R. Paridaens,et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] R. Zeillinger,et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. , 1997, Oncology.
[34] G. Nuovo,et al. Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.
[35] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[36] K. Kuroi,et al. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. , 1992, American journal of surgery.